On July 28, 2026 GSK plc (LSE/NYSE: GSK) licensor Hansoh Pharmaceutical Group Co., Ltd. reported that ARTEMIS-011, its pivotal phase III trial evaluating risvutatug rezetecan (Ris-Rez) in patients with osteosarcoma who have progressed or relapsed after receiving at least two prior lines of systemic therapy, met its primary endpoint of progression-free survival (PFS).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the trial, conducted in patients in China, Ris-Rez, a B7-H3-targeted antibody-drug conjugate (ADC), demonstrated statistically significant and clinically meaningful improvements in PFS compared with chemotherapy. Consistent benefit was also observed across secondary endpoints, including overall survival. The safety profile of ARTEMIS-011 is consistent with prior findings in this tumour type, and no new safety signals were identified. These data will be used by Hansoh Pharma for regulatory submission in China.
GSK is advancing EMBOLD Sarcoma-202, a global phase Ib/II trial of Ris-Rez in previously treated unresectable advanced or metastatic sarcomas, including osteosarcoma. The study is part of GSK’s broader clinical development programme across multiple solid tumours, including lung and prostate cancers, under its exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan. Ris-Rez has US FDA Breakthrough Therapy Designation in relapsed or refractory osteosarcoma.
Today’s results from Hansoh follow recently reported pivotal data in advanced or relapsed small-cell lung cancer (SCLC), making Ris-Rez the only B7-H3-targeted ADC to deliver positive phase III outcomes across multiple tumour types.
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK said: "Building on recent pivotal data in small-cell lung cancer, these results strengthen our confidence in the broad potential of Ris-Rez and validate B7-H3 as a promising target across multiple tumour types."
Osteosarcoma mainly affects children and young adults and is the most common primary bone cancer, accounting for 20-40% of all bone cancers1. It is a rare bone cancer with a global incidence of approximately 3.4 cases per million people per year2. Following first-line chemotherapy, treatment options for patients with relapsed osteosarcoma are severely limited, with no clear standard of care available3. After patients progress on two prior lines of treatment, options become even more limited, with no approved therapies.
About risvutatug rezetecan
Ris-Rez is a novel investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. GSK acquired exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of Ris-Rez.
Regulatory designations received for Ris-Rez to date include orphan drug designations from the US Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare in SCLC and the European Medicines Agency (EMA) in a category of cancer that includes SCLC, called pulmonary neuroendocrine carcinoma; Priority Medicines (PRIME) Designation from the EMA for relapsed or refractory extensive-stage SCLC (ES-SCLC); and Breakthrough Therapy Designations for relapsed or refractory ES-SCLC and relapsed or refractory osteosarcoma from the US FDA.
(Press release, GlaxoSmithKline, JUL 28, 2026, View Source [SID1234669457])